<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28368">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845116</url>
  </required_header>
  <id_info>
    <org_study_id>Omegaven 04-10-18B</org_study_id>
    <nct_id>NCT01845116</nct_id>
  </id_info>
  <brief_title>Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury</brief_title>
  <official_title>Use of a Fish Oil-Based Intravenous Lipid Emulsion (Omegaven®) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolinas Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the omega-3 fatty acid emulsion
      (Omegaven®), when used in place of the conventional soy-based fat emulsion (Intralipid), is
      effective in treating parenteral nutrition associated liver disease (PNALD) in children.

      The study hypothesis is that Omegaven® can be safely provided to children who are dependent
      on parenteral nutrition and have PNALD, and can reverse or prevent progression of PNALD
      until the child can take adequate nutrition by mouth.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of parenteral administration of fish oil derived fat emulsion (Omegaven®) to reverse established parenteral nutrition associated liver disease</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normalization or trend toward normalization of direct bilirubin level</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parenteral Nutrition Associated Liver Disease</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single Omegaven® Intervention Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven®</intervention_name>
    <description>10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>IV Fish Oil Based Lipid Emulsion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 0-18 years of age

          -  Patients will be PN-dependent and expected to continue PN for at least 30 days

          -  Patients considered eligible for study participation must have PN-associated liver
             diseases . Other causes of liver disease (i.e., biliary atresia, galactosemia,
             alpha-1 antitrypsin deficiency) will be excluded. A liver biopsy is not necessary for
             treatment

          -  Direct bilirubin &gt; 2.0 mg/dl

          -  Signed patient informed consent

          -  Signed patient assent where applicable.

        Exclusion Criteria:

          -  Pregnancy

          -  Other causes of chronic liver disease (cystic fibrosis, biliary atresia, alpha-1
             antitrypsin deficiency)

          -  Signs of advanced liver disease including cirrhosis on biopsy, varices, ascites

          -  The patient is allergic to eggs/shellfish

          -  The patient has a severe hemorrhagic disorder

          -  The patient is enrolled in any other clinical trial involving an investigational
             agent (unless approved by the designated physicians on the multidisciplinary team)

          -  The parent or guardian or child unwilling to provide consent or assent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo A. Caicedo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Levine Children's Hospital at Carolinas HealthCare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo A. Caicedo, MD</last_name>
    <phone>704-381-8880</phone>
    <email>ricardo.caicedo@carolinashealthcare.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle K. Chiu, MD</last_name>
    <phone>704-381-4833</phone>
    <email>michelle.chiu@carolinashealthcare.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Levine Children's Hospital at Carolinas HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo A. Caicedo, MD</last_name>
      <phone>704-381-8880</phone>
      <email>ricardo.caicedo@carolinashealthcare.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep;250(3):395-402.</citation>
    <PMID>19661785</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar;121(3):e678-86.</citation>
    <PMID>18310188</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul;118(1):e197-201.</citation>
    <PMID>16818533</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Ricardo Caicedo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PNALD</keyword>
  <keyword>Cholestasis</keyword>
  <keyword>Omegaven®</keyword>
  <keyword>Short Bowel Syndrome</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
